The Compensation Question

Part V of this series documented the mandate architecture — the federal, state, institutional, and private mandates that compelled vaccination of a substantial majority of the American workforce from September 2021 through 2023. Part VI documents what the federal architecture provided, and did not provide, for the people who were injured by what they had been compelled to take. The structural finding is contained in a single statute. The Public Readiness and Emergency Preparedness Act of 2005 — the PREP Act — granted the manufacturers, distributors, and administrators of covered countermeasures near-total immunity from civil liability. The same statute created the Countermeasures Injury Compensation Program, the administrative pathway that, in exchange for the immunity it conferred on industry, was supposed to compensate the people the countermeasures injured. This Part documents how that bargain functioned. The shield was near-total. The remedy, on the program's own published data, reached about one-third of one percent of those who asked.

The constitutional logic of the bargain is foundational to American law. The government may, in certain circumstances, extinguish a person's right to sue — but when it does, it must generally provide an adequate substitute remedy. The workers' compensation system is the classic example: the injured worker gives up the right to sue the employer in tort and receives, in exchange, a no-fault administrative compensation system that pays reliably and promptly. The PREP Act framework was built on the same logic. The injured person gives up the right to sue the vaccine manufacturer; in exchange, the injured person receives access to the Countermeasures Injury Compensation Program. This Part examines whether the substitute remedy was, in operation, adequate. The documentary record establishes that it was not.

The Part proceeds through nine sections. Section I documents the two federal injury-compensation programs and the consequential fact that COVID vaccines fall under the more restrictive of the two. Section II documents the PREP Act liability shield. Section III documents the compensation program that was supposed to replace the courthouse. Section IV documents the numbers — the program's own published data, current to April 2026. Section V documents the five structural barriers that make the program nearly impossible to recover under. Section VI documents the architectural choice not to move the COVID vaccines to the functioning program after they received full approval, and the reform efforts that choice has provoked. Section VII documents the informed-consent architecture, the statutory right to refuse, and the bioethical debate that the mandate architecture provoked. Section VIII documents the open scientific questions — including the carcinogenicity question that the emergency-authorization framework never required anyone to study. Section IX is the discipline section that closes every part of this series.

The Two Programs

The United States operates two distinct federal programs for compensating individuals injured by vaccines and other medical countermeasures. The distinction between them is the single most consequential fact for any person injured by a COVID-19 vaccine, and it is a fact that almost no one knew at the moment they were vaccinated.

The first program is the National Vaccine Injury Compensation Program — the VICP. It was created by the National Childhood Vaccine Injury Act of 1986, in response to a wave of lawsuits over vaccine injuries that had threatened the stability of the childhood-vaccine supply. The VICP covers the vaccines routinely recommended by the Centers for Disease Control and Prevention for children and pregnant women, financed by an excise tax of seventy-five cents per vaccine dose paid into a Vaccine Injury Trust Fund that, as of mid-2024, held approximately $4.5 billion. The VICP is, by the standards of administrative compensation programs, relatively functional. It operates through the United States Court of Federal Claims, where a panel of special masters — the body commonly called the Vaccine Court — adjudicates claims. It permits claimants to be represented by attorneys, and it pays those attorneys' fees and costs out of the trust fund, win or lose. It compensates for pain and suffering, up to a statutory cap, in addition to medical expenses and lost wages. It maintains an Injury Table that lists injuries presumed to be vaccine-caused, shifting the burden of proof for listed injuries. From its inception through December 2024, the VICP processed 14,409 petitions and found 10,633 compensable — a rate reflecting a functioning adjudicative system. The trust fund pays out roughly $125–150 million in compensation each year, plus another $25–30 million in attorneys' fees, without reliance on taxpayer dollars.

The second program is the Countermeasures Injury Compensation Program — the CICP. It was created by the PREP Act in 2005, and it operates on entirely different terms. The CICP covers "covered countermeasures" deployed during a declared Public Health Emergency — the category into which the COVID-19 vaccines fell by virtue of the PREP Act declaration the Secretary of Health and Human Services issued in early 2020. The CICP is administered not by a court but internally, by the Health Resources and Services Administration — HRSA — within HHS. It does not permit recovery of attorney fees. It does not compensate for pain and suffering. It requires claims to be filed within one year. And it maintains no Injury Table for any COVID-19 countermeasure, meaning every claimant must prove direct causation from scratch.

The consequential fact is this: the COVID-19 vaccines, because they were deployed under the PREP Act framework rather than as routine recommended vaccines, fall under the CICP — the restrictive program — and not under the VICP. A person injured by a COVID-19 vaccine does not have access to the Court of Federal Claims, to attorney representation paid by the program, to compensation for pain and suffering, or to an Injury Table. That person has access only to the internal HRSA administrative process that this Part documents.

The Shield

The PREP Act liability shield is the structural foundation on which the entire compensation question rests. The Act, codified at 42 U.S.C. § 247d-6d, authorizes the Secretary of Health and Human Services to issue a declaration providing liability immunity for covered countermeasures during a public health emergency. When the Secretary issued the COVID-19 PREP Act declaration, effective February 4, 2020, that immunity attached to the COVID-19 countermeasures, including the vaccines.

The scope of the immunity is broad. It shields manufacturers, distributors, program planners, and the persons who administer covered countermeasures from civil liability for any loss caused by, arising out of, relating to, or resulting from the administration or use of a covered countermeasure. The single exception is for "willful misconduct" — a standard so demanding that, in the documented history of the PREP Act, it has almost never been met. As a practical matter, the immunity is total.

The operational consequence for the injured person is direct. A person who suffers myocarditis after an mRNA vaccine cannot sue the manufacturer. A person who suffers a thrombosis-with-thrombocytopenia syndrome blood clot after the Janssen vaccine cannot sue the manufacturer. A person who suffers Guillain-Barré syndrome, anaphylaxis, pericarditis, or any of the other documented serious adverse events cannot sue the manufacturer, the distributor, the pharmacy, or the employer who required the vaccine. The courthouse door, which in the ordinary case of a defective product would be open, is closed by federal statute.

This is not, in itself, a scandal. Liability shields for emergency countermeasures serve a genuine purpose: without them, manufacturers might decline to produce vaccines and treatments at the speed an emergency demands, for fear of ruinous litigation. The 1986 VICP was built on the same logic for childhood vaccines. The shield is a defensible policy instrument. The question is not whether the shield should exist. The question is what the people behind the shield were given in exchange for the right the shield took away.

The Remedy That Was Supposed to Replace the Courthouse

What the injured person was given in exchange is the Countermeasures Injury Compensation Program, codified at 42 U.S.C. § 247d-6e. The CICP is, by the statute's design, the exclusive remedy for a person injured by a covered countermeasure. Having been stripped of the right to sue, the injured person's sole recourse is to file a claim with HRSA and to satisfy the program's evidentiary standard.

That standard is the operative barrier. To receive compensation, a claimant must demonstrate, by "compelling, reliable, valid, medical and scientific evidence," that the injury was "directly caused" by the covered countermeasure. The program's own published guidance is explicit that temporal association — the fact that the injury occurred a certain time after the vaccination — is not, by itself, sufficient to prove that the injury was directly caused by the countermeasure. The claimant must establish direct causation affirmatively, with evidence the program characterizes as compelling.

For most injuries, this is an extraordinary burden. The mechanism by which a vaccine causes a particular injury in a particular person is, in the current state of medical science, frequently impossible to establish to the standard of "compelling, reliable, valid medical and scientific evidence." The injured person, navigating the process without an attorney whose fees the program will pay, must assemble medical and scientific evidence sufficient to satisfy a HRSA medical reviewer that the causation is not merely temporally associated but direct. The structural difficulty of this burden is reflected in the program's own data.

The Numbers

The Countermeasures Injury Compensation Program publishes its own data. The figures that follow are drawn from HRSA's published CICP data, current to the program's April 1, 2026 reporting, and from the December 2024 report of the United States Government Accountability Office, GAO-25-107368. They are the documentary core of this Part.

The COVID-19 pandemic produced a surge of CICP claims without precedent in the program's history. The GAO documented that the CICP received approximately twenty-seven times more claims in response to the COVID-19 pandemic than it had received in the entire first decade of the program's existence — 13,333 COVID-related claims, compared to 491 claims in the decade from 2009 to the pandemic. By the program's April 1, 2026 reporting, the total number of COVID-19 countermeasure claims filed had reached 14,147, of which 10,999 alleged injuries or deaths from COVID-19 vaccines. COVID-19 claims account for roughly ninety-six percent of all claims ever filed with the program across its entire history.

The disposition of those claims is the finding. As of April 1, 2026, of the 14,147 COVID-19 claims filed, 7,203 — just over half — remained pending or in review, many of them for years. The program had rendered 6,944 decisions. Of those, 97 claims had been found eligible for compensation. The number actually compensated was 51. Of the 97 found eligible, 43 were still awaiting a benefits determination and 3 had no eligible reported expenses at all — meaning that even the finding of eligibility, in those cases, had produced nothing. Fifty-one compensated claims, out of 14,147 filed, is a compensation rate of approximately one-third of one percent.

The shield was near-total. The remedy, out of 14,147 COVID-19 claims, reached fifty-one people — about one-third of one percent.

The denials tell the rest of the story. Of the 6,847 COVID-19 claims denied as of April 1, 2026, the two largest categories were not denials on the merits at all. The single largest category — 2,636 claims — was denied because the required medical records were never submitted. The second largest — 2,590 claims — was denied because the claimant missed the one-year filing deadline. Only 1,360 of the denials — under twenty percent — turned on the substantive question of whether the standard of proof for causation was met or a covered injury was sustained. The overwhelming majority of denials were procedural: a deadline missed, a record not filed, by people navigating the process alone.

The dollar figures complete the picture. The GAO documented that, as of mid-2024, the CICP had paid roughly $419,000 total for COVID-19 countermeasure injuries — across all claimants, for the entire pandemic. The individual payments for COVID injuries ranged from approximately $1,032 to $370,376. Independent analysis of the program's February 2025 data release found that, excluding the two highest outlier payments, the average CICP payout was approximately $4,000 — an amount that, for most serious injuries, would not cover the cost of the initial emergency-room visit. Most myocarditis claims — myocarditis being the most common compensated injury — received between roughly $1,000 and $5,500. Even the successful claimant, in other words, typically recovered a few thousand dollars of unreimbursed medical expense, with nothing for the pain, the disability, or the life altered.

The comparison that most starkly illustrates the program's operational failure is not to another government program. It is to a private charity. The nonprofit organization React19, which raises private donations to assist people who report COVID-19 vaccine injuries, has paid out more than one million dollars of privately raised money to injured people — more than double what the federal compensation program, funded by the government and backed by the full faith and credit of the United States, had paid for COVID injuries as of the same period. A private charity, passing the hat, out-paid the federal remedy that was supposed to replace the courthouse.

The GAO's report identified, in the program's own administrative record, the structural reasons for the outcome. HRSA took, on average, twenty-four months simply to reach a decision on a claim — with some claims taking thirty-nine months. Missed filing deadlines and unsubmitted medical records together accounted for the large majority of denials. And HRSA officials told the GAO, in language the report documented, that the lack of medical and scientific evidence made it challenging for the program's medical reviewers to determine causality between COVID-19 countermeasures and the alleged injuries. The program demanded compelling evidence of direct causation; the science to produce that evidence, in the program's own assessment, frequently did not exist.

The Barriers

The program's near-zero compensation rate is not an accident of administration. It is the predictable output of five structural barriers built into the CICP's design, each of which stands in contrast to the more functional VICP. The barriers, taken together, explain why a person injured by a compelled COVID-19 vaccine had, as a practical matter, almost no path to compensation.

The One-Year Deadline

The CICP requires that a claim be filed within one year of the administration of the countermeasure. The VICP, by contrast, allows three years. The one-year deadline is an extraordinary barrier for vaccine-injury claims, because many serious injuries are not diagnosed, and many injured people do not connect their injury to the vaccination, within a single year. As of April 2026, 2,590 COVID-19 claims — more than fifty times the number ever compensated — had been denied for missing the one-year window. Thousands of claims were rejected not on their merits but because the injured person did not file in time, against a deadline most claimants did not know existed.

No Attorney Fees

The CICP does not pay attorney fees or costs. The VICP does. The consequence is that a CICP claimant must navigate the program's demanding causation standard, its evidentiary requirements, and its administrative process without legal representation — or must pay for that representation out of any eventual award, which for most claimants would consume the entire award. The result is that most CICP claimants proceed alone, against a federal agency, on a question — medical causation — that the agency's own medical reviewers find difficult.

No Compensation for Pain and Suffering

The CICP compensates only for unreimbursed medical expenses and lost wages, subject to limitations. It does not compensate for pain and suffering. The VICP does, up to a statutory cap. For a person who has suffered a disabling injury — who lives with chronic pain, with permanent disability, with the loss of the life they had before — the CICP offers nothing for the suffering itself. It offers, at most, reimbursement for documented out-of-pocket medical costs that other insurance did not cover.

No Injury Table

The VICP maintains an Injury Table — a list of injuries presumed, for specified vaccines, to be vaccine-caused, which shifts the burden of proof in the claimant's favor for listed injuries. The CICP has issued no Injury Table for any COVID-19 countermeasure. The consequence is that every COVID claimant must prove direct causation from scratch, to the program's "compelling, reliable, valid medical and scientific evidence" standard, with temporal association expressly insufficient. The absence of an Injury Table places the full evidentiary burden on the injured person in every case.

No Court, No Appeal

The CICP is an internal administrative process within HRSA. There is no hearing before an independent tribunal. There is no appeal to a court. The VICP, by contrast, operates through the Court of Federal Claims, with special masters, with the procedural protections of a judicial process, and with judicial review. The CICP claimant who is denied has recourse only to internal HRSA reconsideration. The decision that extinguishes the injured person's claim is made by the same agency that administers the program, with no independent adjudicator and no judicial check.

The five barriers compound. A claimant must discover the injury, connect it to the vaccine, learn that the CICP exists, learn that it is the exclusive remedy, file within one year, proceed without paid counsel, prove direct causation with compelling scientific evidence that the agency itself says frequently does not exist, forgo any compensation for suffering, and accept a decision made by the administering agency with no appeal to a court. The fifty-one compensated claims, out of 14,147 filed, are what this gauntlet produces.

The Door That Was Never Opened

There is a detail in the architecture that transforms the compensation failure from a misfortune into a choice. The COVID-19 vaccines began under Emergency Use Authorization, which is why they fell under the CICP rather than the VICP. But the two principal mRNA vaccines did not stay under emergency authorization. They received full FDA approval — Comirnaty, the Pfizer-BioNTech product, in August 2021, and the Moderna product, Spikevax, in January 2022. And in 2023, the CDC recommended COVID-19 vaccination for routine administration to children and to pregnant women. Both of those developments are, under the governing statutes, steps on the path that would move the COVID-19 vaccines from the restrictive CICP into the functioning VICP. The path exists. It was not taken.

The statutory requirements for a vaccine to be covered by the VICP are documented and specific. The Congressional Research Service has laid them out: a vaccine must be recommended by the CDC for routine administration to children or pregnant women; it must be made subject, by an act of Congress, to the seventy-five-cent excise tax that funds the Vaccine Injury Trust Fund; and the Secretary of Health and Human Services must add it to the Vaccine Injury Table. The first condition — the CDC routine-administration recommendation — was satisfied in 2023. The remaining two have never been completed. Congress has never imposed the excise tax on COVID-19 vaccine doses, and the Secretary has never added the COVID-19 vaccines to the Injury Table.

The consequence of that inaction is twofold, and both halves are consequential. For the injured person, it means that the COVID-19 vaccines remain under the CICP — the program with the one-year deadline, no paid counsel, no compensation for suffering, no Injury Table, and no appeal to a court — rather than under the VICP, the program with the three-year deadline, paid counsel, compensation for suffering, and adjudication before the Vaccine Court. The injured person's forum is determined not by the nature of the product, which is now a fully approved, routinely recommended vaccine, but by the failure to complete the transfer.

For the manufacturers, the same inaction carries a financial dimension. Because the COVID-19 vaccines were never made subject to the seventy-five-cent excise tax, their manufacturers never paid that tax on the hundreds of millions of doses administered in the United States — doses that, had the vaccines been brought under the VICP, would have generated substantial contributions to the trust fund from which the injured are compensated. The product was given to a substantial majority of the American workforce, frequently under compulsion; its manufacturers were shielded from suit; and the trust-fund mechanism that funds compensation for the injured was never extended to the doses they sold.

The mismatch has not gone unrecognized. In June 2024, Representatives Lloyd Doggett and Lloyd Smucker introduced the Vaccine Injury Compensation Modernization Act, bipartisan legislation that would, among other reforms, shift pending COVID-19 vaccine claims from the CICP to the VICP. A companion measure, the Vaccine Access Improvement Act, would streamline the excise-tax mechanism so that the tax applies automatically once the Secretary adds a vaccine to the Injury Table, eliminating the requirement for separate Congressional action each time. Litigation has also been filed seeking to compel the transfer, on the argument that the statutory conditions for VICP coverage have been met and the law requires the move. As of this writing, the COVID-19 vaccines remain under the CICP. The reform proposals document that the mismatch is recognized across the political spectrum; the persistence of the mismatch documents that recognition has not, to date, produced the change.

The structural significance is this. The compensation failure documented in the preceding sections is not, on the full record, simply the product of a program that happened to be a poor fit. It is the product of a program that was a poor fit, paired with the failure to complete the well-documented statutory path that would have moved the injured into a program that fit. The door to the functioning program exists. For the people injured by a compelled, now-fully-approved vaccine, it has not been opened.

The Consent That Was Owed

Beneath the compensation question lies a deeper one, and it returns to the nature of the product itself. The COVID-19 vaccines were deployed, at the outset and for the duration of the mandate period documented in Part V, under Emergency Use Authorization. An Emergency Use Authorization, by its statutory nature, is a mechanism for deploying a medical product that the Food and Drug Administration has not approved through its standard process — a product that remains, in the regulatory sense, investigational.

The EUA statute itself, 21 U.S.C. § 360bbb-3, builds in a specific protection for the individual. The statute directs the Secretary to establish conditions ensuring that individuals to whom an EUA product is administered are informed "of the option to accept or refuse administration of the product, of the consequences, if any, of refusing administration of the product, and of the alternatives." The right to be informed of the option to refuse is written into the emergency-authorization framework by Congress itself. It is a statutory recognition that an investigational product deployed under emergency authorization carries a heightened obligation of informed consent — the individual must be told the product is authorized rather than approved, must be told its known and potential risks and the extent to which those risks are unknown, and must be told that refusal is an option.

The mandate architecture documented in Part V stands in direct tension with this statutory right. The EUA statute guarantees the individual the option to refuse. The mandate architecture converted that option, for a substantial portion of the American workforce, into a choice between vaccination and the loss of employment, education, healthcare access, or military service. The statutory right to refuse and the mandate that penalized refusal are, on the documentary record, in tension that the courts have not fully resolved.

This tension provoked one of the most contested bioethical debates of the pandemic period. Critics — including physicians, bioethicists, and legal scholars — argued that mandating an investigational product deployed under emergency authorization, enforced by the loss of livelihood, undermined the voluntariness that informed consent requires, and implicated the first principle of the Nuremberg Code: that the voluntary consent of the human subject is essential. The argument draws on the framework of research ethics — the Nuremberg Code, the Declaration of Helsinki, the federal protections for human research subjects — that requires free, uncoerced, informed consent for participation in medical experimentation.

The counterargument, advanced in the peer-reviewed bioethics literature, is also documented and deserves a fair statement. The defenders of mandates argue that the COVID-19 vaccines, once authorized or later approved by the FDA, were not "experimental" in the research sense; that administering an authorized public-health countermeasure is a public-health intervention, not human-subjects research; and that the Nuremberg Code, which governs research, does not apply to public-health practice. On this view, a vaccine mandate is a public-health measure of the same general kind as longstanding school-vaccination requirements, and the Nuremberg framing is a category error.

The honest assessment the documentary record supports is that the strongest form of the critics' argument does not rest on the claim that mandates are literally Nazi medical experimentation — a claim that overshoots and that the bioethics defenders correctly reject. The strongest form rests on the narrower, documented tension: that an EUA product carries, by statute, a right to refuse; that the product was, in the regulatory sense, investigational; that long-term safety data was, by the nature of emergency authorization, not yet developed; and that the mandate architecture penalized the exercise of the statutory right to refuse. On that narrower ground — not on the inflammatory analogy — the tension between the mandate architecture and the informed-consent framework is real and documented.

The Questions the Emergency Never Required Anyone to Answer

The Emergency Use Authorization framework permits deployment of an investigational product on an abbreviated evidentiary record. That is its purpose: to make a countermeasure available in an emergency faster than the standard approval process would allow. The trade-off is that certain studies the standard process would require are not completed before deployment. Among the studies that the emergency framework did not require before the COVID-19 vaccines were deployed to hundreds of millions of people were long-term carcinogenicity and genotoxicity studies — the studies that assess whether a product is associated, over time, with the development of cancer.

This is not a contested claim. It is a feature of the emergency-authorization framework. Standard vaccine licensure does not always require carcinogenicity studies either; but the point relevant here is that the abbreviated EUA record meant that the long-term oncologic surveillance infrastructure — the systematic, population-scale, long-horizon study of cancer incidence in the vaccinated versus the unvaccinated — was never built before deployment, and has, in substantial part, still not been built. The emergency framework did not require the creation of the linked databases and cohort infrastructure that would have allowed a rigorous comparison of cancer incidence between vaccinated and unvaccinated populations at scale and over time. For a product deployed under compulsion to hundreds of millions of people, the surveillance system that would answer the question of its long-term effects was, by the design of the framework that authorized it, never required to exist.

The consequence is that, as of early 2026, the scientific record on the relationship between COVID-19 vaccination and cancer is genuinely unsettled — and the absence of definitive evidence is itself a documented gap. A systematic review published in the peer-reviewed journal Oncotarget in January 2026, led by researchers at Tufts University School of Medicine and the Warren Alpert Medical School of Brown University, examined sixty-nine publications from 2020 to 2025 describing cancers appearing in temporal association with COVID-19 vaccination or infection. The review's authors concluded that the collective evidence underscores what they termed a "biologically plausible connection" between COVID-19 vaccination and cancer, proposed a mechanism of tumor hyperprogression, and called for systematic genomic surveillance and larger cohort studies to define the question rigorously.

The same review was candid about the limits of the current evidence. Its authors documented that there are no published United States population studies with cancer-incidence or mortality follow-up beyond a short window comparing vaccinated and unvaccinated cohorts — in part because the high-quality databases that would permit such a study do not exist. The review's signal is a call for investigation, not a finding of established causation.

The countervailing evidence is also documented and must be stated. The major cancer registries — the SEER program in the United States, the international GLOBOCAN database — have not reported cancer-incidence spikes attributable to vaccination. The documented rise in early-onset cancers in recent years predates the pandemic and is associated in the literature with other factors. And a 2025 study published in Nature reported that SARS-CoV-2 mRNA vaccines may actually sensitize certain tumors to immune-checkpoint blockade — that is, may in some oncologic contexts enhance, rather than undermine, anti-tumor immunity. The same vaccine platform that the Oncotarget review flagged for investigation appears, in the Nature study, as potentially beneficial in cancer treatment.

The honest conclusion the documentary record supports is not that COVID-19 vaccination causes cancer. The documentary record does not establish that, and this Part does not assert it. The honest conclusion is that the question is open; that serious researchers at major institutions have found signals they consider worth rigorous investigation; that countervailing evidence exists; and that the surveillance infrastructure needed to resolve the question definitively was never built — because the emergency-authorization framework that deployed the product to hundreds of millions of people never required anyone to build it. For a product administered under compulsion to a substantial majority of the American workforce, the absence of the long-term safety surveillance that would answer the question is, in itself, the documented failure.

The question is open. The signal is under study. The surveillance to answer it was never built. For a product deployed under compulsion, that absence is itself the failure.

What This Part Establishes

This Part has documented a compensation architecture. It has not, deliberately, made certain claims that the documentary record does not support.

It has not established that COVID-19 vaccines caused any particular injury in any particular person. The injuries this Part references — myocarditis, pericarditis, thrombosis-with-thrombocytopenia syndrome, Guillain-Barré syndrome, anaphylaxis — appear in the documentary record because the Countermeasures Injury Compensation Program's own eligibility findings, made by the government's own medical reviewers, concluded that those injuries, in the specific compensated cases, were directly caused by a covered countermeasure. The causation conclusions referenced in this Part are the government's own, in the cases the government itself compensated. This Part asserts no independent causation finding.

It has not established that COVID-19 vaccines cause cancer. The documentary record establishes that the question is open, that serious researchers have identified signals worth investigating, that countervailing evidence exists, and that the surveillance infrastructure to resolve the question was never built. The open question, not a causation finding, is what this Part documents.

It has not established that the PREP Act liability shield is unconstitutional, or that liability shields for emergency countermeasures are illegitimate. Liability shields serve a genuine policy purpose, and the constitutional logic of substituting an administrative remedy for the right to sue is well established. The structural concern documented in this Part is not that the shield exists, but that the substitute remedy the shield was paired with did not, in operation, function as an adequate substitute.

It has not established that vaccine mandates are literally equivalent to the human experimentation the Nuremberg Code was written to prohibit. The strongest form of the informed-consent argument, as this Part has documented, rests not on that analogy but on the narrower and documented tension between the EUA statute's guarantee of a right to refuse and the mandate architecture that penalized refusal.

What this Part does establish is that a single 2005 statute granted near-total liability immunity to the manufacturers of covered countermeasures and created the compensation program meant to replace the right to sue that the immunity extinguished; that the COVID-19 vaccines fell under the more restrictive of the two federal compensation programs, the CICP, by virtue of the PREP Act declaration; that the CICP, on its own published data as of April 2026, had received 14,147 COVID-19 claims and compensated fifty-one — about one-third of one percent — with most denials turning on missed deadlines and unsubmitted records rather than the merits; that the total federal payout for COVID-19 countermeasure injuries was exceeded, more than twofold, by the privately raised funds of a single charity; that five structural barriers — the one-year deadline, the absence of paid counsel, the absence of compensation for suffering, the absence of an Injury Table, and the absence of any court or independent appeal — account for the near-zero compensation rate; that the COVID-19 vaccines, though fully approved and recommended for routine administration since 2023, were never moved to the functioning VICP through the documented statutory path, and their manufacturers therefore never paid the excise tax that funds the trust fund from which the injured are compensated; that the EUA statute guarantees a right to refuse that the mandate architecture documented in Part V penalized; and that the long-term safety surveillance that would answer the open scientific questions about an investigational product deployed under compulsion was never built.

The documentary record speaks. A person was told, in many cases, that they must take a product or lose their livelihood. The product was, in the regulatory sense, investigational. The statute that governed its deployment guaranteed that person the right to refuse — a right the mandate hollowed out. When the product injured that person, the manufacturer was immune from suit. The remedy the law provided in exchange for that immunity compensated fifty-one people out of more than fourteen thousand who asked, while the door to the functioning program stood unopened. And the studies that would establish what the product did, or did not do, over the long term to the people compelled to take it were never required, and in substantial part were never done. That is the architecture. The next Part of this series will examine the internal communications of the officials who built it.